chronic inflammatory demyelinating polyneuropathy


Also found in: Dictionary, Financial, Acronyms, Wikipedia.

chron·ic in·flam·ma·to·ry de·my·e·li·nat·ing pol·y·neu·rop·a·thy (CIDP),

an uncommon, acquired, demyelinating sensorimotor polyneuropathy, clinically characterized by insidious onset, slow evolution, (either steady progression or stepwise), and chronic course; symmetric weakness is a predominant symptom, often involving proximal leg muscles, accompanied by paresthesias, but not pain; CSF examination shows elevated protein, whereas electrodiagnostic studies reveal evidence of a demyelinating process, primarily conduction slowing rather than block; sometimes responds to prednisone.

chronic inflammatory demyelinating polyneuropathy (CIDP)

a slowly progressive autoimmune neurological disorder with demyelination of the peripheral nerves and nerve roots, characterized by progressive weakness and impaired sensory function (loss of reflexes) in the limbs and enlargement of the peripheral nerves and usually by elevated protein in the cerebrospinal fluid. It occurs most commonly in young adults, particularly males. Presenting symptoms often include tingling or numbness of the digits, weakness of the limbs, hyporeflexia or areflexia, fatigue, and abnormal sensations. It is similar to Guillain-Barré syndrome but has a slower onset and lasts much longer.

chronic inflammatory demyelinating polyneuropathy

Abbreviation: CIDP
A gradually progressing autoimmune muscle weakness in arms and legs caused by inflammation of the myelin sheath covering peripheral nerve axons. Demyelination slows or blocks conduction of impulses to muscles. Numbness and paresthesia may accompany or precede loss of motor function, which varies from mild to severe. Laboratory findings include elevated protein levels in the cerebrospinal fluid. The inflammatory damage involves not only phagocytes (neutrophils and macrophages), but also immune complexes and complement activation by myelin autoantigens. Immunosuppressive drugs are used to treat this illness. Plasma exchange therapy or infusions of immunoglobulins often are used first, to produce a remission. CIDP is considered to be a chronic counterpart to Guillain-Barré syndrome.
See also: polyneuropathy
References in periodicals archive ?
Chronic inflammatory demyelinating polyneuropathy accompanied by hepatocellular carcinoma.
Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy.
The spectrum of chronic inflammatory demyelinating polyneuropathy.
Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy.
Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP).
Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin.
Gamunex is indicated as replacement therapy of primary humoral immunodeficiency disease (PI), and as immunomodulatory therapy for both idiopathic thrombocytopenic purpura (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP).
Gamunex, Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified, is indicated for the treatment of primary humoral immunodeficiency disease (PI), idiopathic thrombocytopenic purpura (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder often characterized by progressive weakness and impaired sensory function in the legs and arms.
Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).
Neurologists and other healthcare providers treating patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) now have access to a peer-reviewed, comprehensive clinical and scientific information center at http://www.
An opportunity to subscribe to quarterly e-mail updates from The Chronic Inflammatory Demyelinating Polyneuropathy Information Center

Full browser ?